Home Cart Sign in  
Chemical Structure| 344897-95-6 Chemical Structure| 344897-95-6

Structure of Leukadherin-1
CAS No.: 344897-95-6

Chemical Structure| 344897-95-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Leukadherin-1 is allosteric activator of CD11b/CD18 with EC50 value of 4 μM for increasing CD11b/CD18-dependent cell adhesion to fibrinogen.

Synonyms: Leukadherin-1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Leukadherin-1

CAS No. :344897-95-6
Formula : C22H15NO4S2
M.W : 421.49
SMILES Code : O=C(O)C1=CC=C(C2=CC=C(C=C(SC(N3CC4=CC=CC=C4)=S)C3=O)O2)C=C1
Synonyms :
Leukadherin-1
MDL No. :MFCD01151276
InChI Key :AEZGRQSLKVNPCI-UNOMPAQXSA-N
Pubchem ID :5342077

Safety of Leukadherin-1

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H319-H332-H372-H400
Precautionary Statements:P260-P264-P270-P273-P280-P301+P312+P330-P304+P312-P305+P351+P338-P314-P337+P313-P391-P501
Class:9
UN#:3077
Packing Group:

Related Pathways of Leukadherin-1

cytoskeleton

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Nonclassical monocytes (NCMs) 20 μM 15 minutes LA-1 pretreatment significantly reduced CXCL2 production induced by TLR agonists, LES, or HMGB1 PMC9282933
Bone marrow-derived dendritic cells (BMDCs) 20 µM 2 hours To evaluate the effect of Loratadine on dendritic cell antigen-presenting function, results showed that Loratadine significantly reduced the production of IL-4, IL-13, and IL-17A PMC6379471
Bone marrow-derived macrophages (BMDMs) 20 µM 2 hours TsV alone induces significant production of IL-1β, demonstrating that the venom itself delivers signals necessary for inflammasome activation in BMDMs. PMC6379471
Human monocyte-derived macrophages (HMDMs) 5 or 10 µg/ml 30 min (post-LPS priming) Confirmed LA1's inhibition of NLRP3 inflammasome in human macrophages, showing reduced IL-1β secretion. PMC11922956
Bone marrow-derived macrophages (BMDMs) 5 µg/ml 24 hours TsV alone induces significant production of IL-1β, demonstrating that the venom itself delivers signals necessary for inflammasome activation in BMDMs. PMC11922956
Wild-type bone marrow-derived macrophages (WT BMDMs) 10 μmol/L 2 hours To investigate the effect of CD11b agonist LA-1 on macrophage adhesion, results showed that LA-1 significantly increased the number of WT BMDMs adhering to endothelial cells. PMC8174368

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice LLC lung cancer model Intraperitoneal injection 2 mg/kg Once daily until the end of the experiment To evaluate the effect of LA1 on tumor growth, results showed LA1 suppresses tumor growth by activating CD11b PMC6300665
Mice APAP-induced liver injury model Intraperitoneal injection 0.4 mg/kg Administered at 6 and 12 hours after APAP administration Enhanced hepatic MMP12 mRNA and reduced necrosis in APAP-treated mice PMC5362307
Mice Allogeneic lung transplant model Intravenous injection 2 mg/kg Single dose, 2 hours before transplantation LA-1 pretreatment significantly reduced neutrophil infiltration in the lung allograft and attenuated histologic evidence of PGD PMC9282933
Mice APP transgenic mice Intraperitoneal injection 50 µM Once daily for 10 days To evaluate the effect of LA-1 on Aβ levels PMC5379986
C57BL/6 mice Endotoxic shock model Intraperitoneal injection 10, 20, 40 µg/g body weight Single injection, observed for 12 hours LA1 significantly reduced the mortality of mice, alleviated pathological injury of liver and lung, and inhibited LPS-induced pro-inflammatory response in macrophages. Additionally, LA1 reduced the levels of IL-6, TNF-α, IL-12, and IL-1β in serum. PMC6379471
Mice Hypertensive cardiac remodeling model induced by Ang II or DOCA-salt Systemic administration 2.5 mg/kg Daily for 14 days To evaluate the effect of CD11b agonist LA1 on cardiac remodeling. Results showed that LA1 significantly exacerbated Ang II-induced cardiac remodeling and dysfunction. PMC10770112
Newborn rats Hyperoxia-induced neonatal lung injury model Intraperitoneal injection 1 mg/kg Twice daily for 14 days LA1 reduced hyperoxia-induced macrophage infiltration, improved alveolarization and vascular development, and decreased pulmonary vascular remodeling and pulmonary hypertension. PMC4742935
ICR mice Transient middle cerebral artery occlusion model Intraperitoneal injection 1 mg/kg Once daily for 3 days Leukadherin-1 reduced brain atrophy volume and neurological deficits at 14 days after ischemia and increased synaptophysin and PSD-95 expression. PMC9941864

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.37mL

0.47mL

0.24mL

11.86mL

2.37mL

1.19mL

23.73mL

4.75mL

2.37mL

References

 

Historical Records

Categories